Search for: "Johnson v. Eli Lilly and Co."
Results 1 - 20
of 72
Sorted by Relevance
|
Sort by Date
1 Apr 2011, 7:30 am
Eli Lilly & Co., 65 Va. [read post]
26 Sep 2008, 10:19 am
Maryland's top court recently affirmed summary judgment for defendant Eli Lilly & Co., in a case brought by a widow whose husband was killed in an auto accident. [read post]
26 Jun 2013, 6:43 am
It is therefore insufficient: see Novartis AG v Johnson & Johnson Medical Ltd [2010] EWCA Civ 1039, [2011] ECC 10 at [77]. [read post]
29 May 2012, 11:48 am
Eli Lilly & Co., 2012 U.S. [read post]
24 May 2012, 12:02 pm
Eli Lilly & Co. and Jirak et al. v. [read post]
6 Oct 2008, 5:00 am
Eli Lilly & Co., No. [read post]
7 Jun 2011, 11:06 am
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
13 Nov 2015, 11:40 am
Eli Lilly & Co., 598 F.3d 1336, 1351(Fed. [read post]
9 May 2012, 11:09 am
Johnson & Johnson and Baum v. [read post]
10 Jan 2012, 11:58 pm
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
8 May 2023, 5:24 pm
Eli Lilly & Co., 503 F. [read post]
7 Nov 2014, 5:52 am
Eli Lilly & Co., 394 F. [read post]
9 May 2012, 11:09 am
Johnson & Johnson and Baum v. [read post]
14 Jul 2011, 2:00 am
(Eli Lilly & Co. case). [read post]
14 Jul 2011, 2:00 am
(Eli Lilly & Co. case). [read post]
26 Jan 2011, 10:04 am
Eli Lilly & Co., 598 F.3d 1336, 1347 (Fed. [read post]
23 Jan 2018, 7:29 pm
Cir. 2015) (citing Eli Lilly & Co. v. [read post]
24 May 2012, 1:02 pm
Eli Lilly & Co. and Jirak et al. v. [read post]
9 Apr 2009, 7:52 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US CAFC clarifies obviousness standard in context of cDNA cloning invention: In re Kubin (Holman's Biotech IP Blog) (Patent Docs) (Hal Wegner) (Philip Brooks' Patent Infringement Updates) (Patently-O) (Patent Docs) Xigris (Drotrecogin alfa) –US: CAFC: Pioneering claims require more expansive written description: Ariad… [read post]
25 May 2011, 8:52 pm
From the pharmaceutical industry, amicus briefs were filed by Apotex; Sanofi-Aventis; Eli Lilly & Co.; BIO; Eisai; Johnson & Johnson; PhRMA; Teva; and GPhA. [read post]
